HSF Translational Research Grant Program supports early-career faculty pursuing novel hidradenitis suppurativa research that connects science to patient care and builds a path to long-term funding.
Funder: Hidradenitis Suppurativa Foundation
Due Dates: December 7, 2026, at midnight (Application) | March 2027 (Notification) | June 1, 2027–May 31, 2028 (Project period)
Funding Amounts: Up to $100,000 in direct costs for one year; up to two new grants annually
Summary: Supports novel translational hidradenitis suppurativa research that can improve patient care and position investigators for long-term funding.
Key Information: Intended for early-career faculty working in the United States, within 10 years of terminal degree or residency completion.
The Hidradenitis Suppurativa Foundation (HSF) Translational Research Grant Program supports novel research ideas in hidradenitis suppurativa (HS) that could compete for future long-term funding from the National Institutes of Health or other agencies. The program is intended for early-career faculty and emphasizes research that connects scientific investigation to patient care.
Proposals should explain the significance and innovation of the research, its contribution to existing knowledge, and its anticipated impact on patients. Review emphasizes rigorous strategies, appropriate methods and analyses, investigator capability, and a credible path to additional funding. HSF also considers patient and caregiver input in study conception, design, and completion, alongside diversity within research teams and patient cohorts. Animal research and development of HS animal models may be considered when clearly connected to human translational research.